SCHEMBL10007610

SCHEMBL10007610

CCN(C)C(=O)n1c(=O)n(C)c2nc(Cc3cccc(C)c3)ncc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 4/20 0.41
▸ GRIN1 Q05586 3/20 0.41
▸ MAOA P21397 2/20 0.39
▸ MAOB P27338 2/20 0.39
▸ HTR2C P28335 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ ACSL1 P33121 1/20 0.37
▸ ALDH1A1 P00352 8/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ GFER P55789 1/20 0.37
▸ LMNA P02545 6/20 0.37
▸ MAPT P10636 3/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ HTT P42858 4/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006561 0.90 MAOA (0.40) GRIN2BGRIN1MAOAMAOBHTR2C
SCHEMBL10006781 0.90 TSPO (0.40) MAOAMAOBALDH1A1SMN1; SMN2MEN1
SCHEMBL10006851 0.89 TRPV1 (0.36) GRIN2BGRIN1MAOBHTR2CHTR2B
SCHEMBL10006747 0.89 MAOA (0.42) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL10006926 0.84 GAA (0.36) GRIN2BGRIN1MAOAMAOBHTR2C
SCHEMBL10007454 0.82 GABRG2 (0.38) MAOBHTR2CALDH1A1LMNAMAPT
SCHEMBL10006445 0.82 POLB (0.43) GRIN2BGRIN1MAOAMAOBHTR2C
SCHEMBL10267698 0.79 TAS2R14 (0.41) GRIN2BGRIN1
SCHEMBL10007102 0.78 ALDH1A1 (0.36) GRIN2BGRIN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL10292527 0.77 MAOB (0.36) GRIN2BGRIN1MAOBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT GRIN2B 635/4885GRIN1 718/4885MAOA 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback